ORIC Pharmaceuticals to Present Phase 1b Enozertinib Data in First-Line Lung Cancer at ESMO 2026

By Public Technologies
  • ORIC Pharmaceuticals will review ongoing Phase 1b enozertinib trial data during an October 23, 2026, webcast at 8 a.m. ET.
  • The study targets previously untreated metastatic lung cancer with atypical EGFR mutations; findings will be presented October 26 at ESMO Congress.
  • Other planned presentations include a Phase 3 rinzimetostat combination study in previously treated metastatic prostate cancer.
  • A separate rinzimetostat poster reports restricted cellular plasticity in preclinical models and mechanistic proof of concept in prostate cancer patient samples.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9847738) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.